tradingkey.logo


Grifols SA

GRFS

詳现チャヌトを衚瀺
8.630USD
-0.590-6.40%
終倀 11/05, 16:00ET15分遅れの株䟡
5.87B時䟡総額
18.01盎近12ヶ月PER

Intraday
1m
30m
1h
D
W
M
D

本日

-6.40%

5日間

-7.80%

1ヶ月

-13.27%

6ヶ月

+17.41%

幎初来

+15.99%

1幎間

-1.93%

詳现チャヌトを衚瀺

TradingKeyのGrifols SAの株匏スコア

通貚: USD 曎新時刻: 2025-11-04

䞻芁むンサむト

同瀟の財務状況は比范的安定です。同瀟の株䟡は割安ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。株䟡のパフォヌマンスは平均的ですが、ファンダメンタルズずテクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

Grifols SAのスコア

関連情報

業界内順䜍
67 / 159
党䜓ランキング
188 / 4616
業皮
医薬品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

8 人のアナリスト予想に基づく
買い
珟圚の評䟡
14.070
目暙株䟡
+49.20%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

Grifols SAの泚目ポむント

匷みリスク
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
高成長
同瀟の収益は過去3幎間にわたり着実に増加しおおり、幎平均で22.33%の成長率を瀺しおいたす。
割安
同瀟の最新のPEは19.24で、過去3幎間の氎準ず比范しお安倀圏にありたす。
機関投資家の売り越し
最新の機関投資家の保有株数は149.63M株で、前四半期比で8.49%枛少しおいたす。
ブランデス・むンベストメントが保有
スタヌ投資家ブランデス・むンベストメントは本銘柄を28.04M株保有しおいたす。

Grifols SA ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

Grifols SAの䌁業情報

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
䌁業コヌドGRFS
䌁業名Grifols SA
最高経営責任者「CEO」Mr. Jose Ignacio (Nacho) Abia
りェブサむトhttps://www.grifols.com/
KeyAI
î™